How Painkillers Work: From Aspirin to Opioids

The Biology of Pain

Pain begins when specialized nerve endings called nociceptors detect potentially harmful stimuli: extreme temperatures, intense pressure, or chemical signals released by damaged tissue. When cells are injured, their membranes break down and release arachidonic acid, a 20-carbon fatty acid normally embedded in cell membrane phospholipids. Enzymes called cyclooxygenases (COX) convert arachidonic acid into prostaglandins, thromboxanes, and prostacyclins, collectively known as prostanoids.

Prostaglandins do not directly cause pain. Instead, they sensitize nociceptors, lowering their activation threshold so that normally innocuous stimuli become painful. This sensitization is called hyperalgesia. Prostaglandins also promote inflammation by increasing blood vessel dilation (causing redness and warmth), increasing vascular permeability (causing swelling), and attracting immune cells to the injury site. In the hypothalamus, prostaglandins raise the body's thermostat set point, producing fever.

Pain signals travel from nociceptors along sensory neurons to the dorsal horn of the spinal cord, where they are processed and relayed to the brain. The brain does not passively receive pain signals. It actively modulates them through descending pathways that can either amplify or suppress pain transmission at the spinal cord level. These descending pathways use neurotransmitters including serotonin, norepinephrine, and endogenous opioid peptides (endorphins, enkephalins, dynorphins). Many analgesics work by leveraging these natural pain-modulation systems.

NSAIDs: Blocking Prostaglandin Production

Non-steroidal anti-inflammatory drugs (NSAIDs) are the most widely used class of analgesics worldwide. They include over-the-counter drugs like ibuprofen (Advil, Motrin), naproxen (Aleve), and aspirin, as well as prescription drugs like diclofenac, ketorolac, and meloxicam. All NSAIDs share a common mechanism: they inhibit cyclooxygenase (COX) enzymes, reducing the conversion of arachidonic acid to prostaglandins.

Two COX isoforms are clinically important. COX-1 is constitutively expressed in most tissues and produces prostaglandins that perform housekeeping functions: maintaining the protective mucus lining of the stomach, supporting kidney blood flow, and enabling platelet aggregation (through thromboxane A2 production). COX-2 is induced at sites of inflammation and tissue injury and produces the prostaglandins primarily responsible for pain, swelling, and fever. Most traditional NSAIDs inhibit both COX-1 and COX-2, which explains both their therapeutic effects (mediated by COX-2 inhibition) and their major side effects (mediated by COX-1 inhibition).

The main side effects of non-selective NSAIDs are gastrointestinal damage (stomach ulcers, bleeding, perforation), reduced kidney function (because prostaglandins help maintain renal blood flow), and increased bleeding time (because platelet thromboxane A2 production is blocked). These effects are dose-dependent and more common with prolonged use. Taking NSAIDs with food or using enteric-coated formulations reduces but does not eliminate gastrointestinal risk.

Aspirin is unique among NSAIDs because it irreversibly acetylates the COX enzyme, permanently inactivating it. Other NSAIDs bind reversibly and are displaced as the drug is cleared. Because platelets cannot synthesize new protein (they lack a nucleus), aspirin's irreversible COX-1 inhibition eliminates platelet thromboxane A2 production for the entire 7 to 10 day lifespan of the platelet. This is why low-dose aspirin (75 to 100 mg daily) is used to prevent heart attacks and strokes: by reducing platelet aggregation, it decreases the risk of blood clots forming in coronary and cerebral arteries.

COX-2 selective inhibitors (celecoxib, the only one still on the market in most countries) were developed to provide anti-inflammatory and analgesic effects while sparing COX-1 and its protective functions. Celecoxib does cause fewer gastrointestinal ulcers than traditional NSAIDs. However, the selective COX-2 inhibitor rofecoxib (Vioxx) was withdrawn in 2004 after clinical trials revealed an increased risk of heart attacks and strokes. The cardiovascular risk appears to relate to the imbalance created when COX-2 derived prostacyclin (which is vasodilatory and anti-thrombotic) is suppressed while COX-1 derived thromboxane (which promotes platelet aggregation) is preserved.

Acetaminophen: A Different Mechanism

Acetaminophen (paracetamol, sold as Tylenol in the US) is the most widely used analgesic and antipyretic in the world. It relieves mild to moderate pain and reduces fever but has minimal anti-inflammatory activity. Despite being used clinically since 1893, its exact mechanism of action remains incompletely understood, making it one of pharmacology's most enduring puzzles.

The leading hypothesis is that acetaminophen inhibits COX activity specifically in the central nervous system. Unlike NSAIDs, which inhibit COX in peripheral tissues as well, acetaminophen appears to have little effect on peripheral prostaglandin synthesis, explaining why it does not reduce inflammation or affect platelet function. Some researchers propose that acetaminophen inhibits a COX variant called COX-3, though this remains controversial. Another proposed mechanism involves the conversion of acetaminophen to AM404, a metabolite that activates cannabinoid CB1 receptors and inhibits the reuptake of the endocannabinoid anandamide, potentially explaining its analgesic effects through the endocannabinoid system. Acetaminophen may also activate descending serotonergic pain inhibition pathways in the brainstem.

The major risk of acetaminophen is hepatotoxicity (liver damage) in overdose. At therapeutic doses, acetaminophen is metabolized safely through glucuronidation and sulfation in the liver. A small fraction is oxidized by CYP2E1 to a toxic reactive metabolite called NAPQI (N-acetyl-p-benzoquinone imine), which is immediately neutralized by glutathione. In overdose, the glucuronidation and sulfation pathways become saturated, more acetaminophen is shunted to the CYP2E1 pathway, and glutathione stores are depleted. The accumulating NAPQI reacts with liver cell proteins, causing oxidative stress, mitochondrial dysfunction, and ultimately hepatocyte death. Acetaminophen overdose is the leading cause of acute liver failure in the United States and United Kingdom. The antidote, N-acetylcysteine (NAC), works by replenishing glutathione stores and is highly effective when given within 8 to 10 hours of the overdose.

Opioid Analgesics: Activating the Brain's Pain Suppression System

Opioid analgesics are the most powerful pain-relieving drugs available. They include natural opiates derived from the opium poppy (morphine, codeine), semi-synthetic derivatives (oxycodone, hydrocodone, heroin), and fully synthetic opioids (fentanyl, methadone, tramadol). All work by activating opioid receptors, the same receptors normally activated by the body's endogenous opioid peptides (endorphins, enkephalins, dynorphins).

Three main opioid receptor types mediate drug effects. The mu receptor is the primary target for analgesia and is responsible for most of the clinically desired and undesired effects of opioid drugs: pain relief, euphoria, respiratory depression, constipation, and physical dependence. The kappa receptor produces analgesia with less euphoria and respiratory depression but can cause dysphoria and hallucinations. The delta receptor contributes to analgesia and has anxiolytic properties. Most clinically used opioids are primarily mu-receptor agonists.

When an opioid agonist binds to the mu receptor (a Gi-coupled GPCR), it activates an inhibitory G protein that reduces cAMP production, opens potassium channels (hyperpolarizing the neuron), and closes calcium channels (reducing neurotransmitter release). In the spinal cord dorsal horn, opioids reduce the release of substance P and glutamate from primary afferent nociceptors, decreasing pain signal transmission. In the brainstem, opioids activate descending inhibitory pathways that suppress pain processing at the spinal level. In the limbic system, opioids modulate the emotional component of pain, making the pain feel less distressing even when the patient is still aware of the sensation.

The side effects of opioids are direct extensions of their pharmacology. Respiratory depression, the most dangerous side effect, occurs because mu receptors in the brainstem's respiratory center reduce the sensitivity of chemoreceptors to carbon dioxide, slowing the breathing rate. Constipation occurs because mu receptors in the gut reduce peristalsis and increase water absorption. Nausea and vomiting result from activation of the chemoreceptor trigger zone in the medulla. Miosis (pupil constriction) occurs because mu receptors stimulate the Edinger-Westphal nucleus, which controls the pupillary sphincter.

Tolerance develops with chronic use, requiring higher doses to achieve the same analgesic effect. Tolerance to analgesia, euphoria, and respiratory depression develops relatively quickly, but tolerance to constipation develops slowly, which is why opioid-induced constipation remains a persistent problem for patients on long-term opioid therapy. Physical dependence develops alongside tolerance: abruptly stopping opioids after chronic use causes a withdrawal syndrome (anxiety, sweating, diarrhea, muscle aches, insomnia) driven by the upregulation of cAMP signaling pathways that were chronically suppressed by the drug.

Comparing Analgesic Classes

Each analgesic class has a distinct pharmacological profile that determines its clinical niche. NSAIDs are most effective for inflammatory pain (arthritis, sports injuries, dental pain, menstrual cramps) because they reduce the prostaglandins driving the inflammatory process. They have a ceiling effect: increasing the dose beyond a certain point does not provide additional pain relief but does increase side effects. Acetaminophen is effective for mild pain and fever but lacks anti-inflammatory activity, making it less useful for inflammatory conditions. Its favorable side effect profile (no GI bleeding, no platelet effects) makes it suitable for patients who cannot take NSAIDs.

Opioids are reserved for moderate to severe pain (postoperative pain, cancer pain, acute trauma) because of their superior analgesic potency but also their significant side effect and addiction profile. They are most effective for nociceptive pain (caused by tissue damage) and less effective for neuropathic pain (caused by nerve damage), though some opioids like tramadol and tapentadol have additional mechanisms (norepinephrine and serotonin reuptake inhibition) that help with neuropathic components.

Multimodal analgesia, the combination of analgesics with different mechanisms, is a cornerstone of modern pain management. Combining an NSAID with acetaminophen provides better pain relief than either drug alone because they reduce prostaglandins through different mechanisms at different sites. Adding an opioid to this combination for severe pain allows lower opioid doses, reducing opioid-related side effects while maintaining effective analgesia. This opioid-sparing strategy is particularly important in the context of the opioid crisis.

Emerging Analgesic Approaches

Research into novel pain mechanisms is producing new analgesic targets. CGRP inhibitors (erenumab, fremanezumab, galcanezumab) block calcitonin gene-related peptide, a neuropeptide involved in migraine pathophysiology, and represent the first class of drugs specifically developed for migraine prevention. Nerve growth factor (NGF) antibodies (tanezumab) target a growth factor that sensitizes nociceptors, showing promise for osteoarthritis and chronic pain conditions. Sodium channel blockers targeting the Nav1.7 channel, which is selectively expressed in nociceptors, are in development based on the observation that people with loss-of-function mutations in the SCN9A gene (encoding Nav1.7) are completely insensitive to pain but otherwise neurologically normal.

The endocannabinoid system is another area of active research. Cannabinoid CB1 and CB2 receptors modulate pain processing, and fatty acid amide hydrolase (FAAH) inhibitors and monoacylglycerol lipase (MAGL) inhibitors aim to boost endocannabinoid levels at the site of pain without the psychoactive effects of directly activating cannabinoid receptors.